## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3

In re Application of:

HSIAO et al.

Application No:

**Initial Filing** 

International Filing Date:

27 June 2003

Priority Date:

27 June 2002

International Appl. No.:

PCT/US2003/020587

Attorney Docket Number:

32144183.4

For:

PLASMA OR SERUM MARKER AND PROCESS FOR

DETECTION OF CANCER

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Commissioner:

## INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant(s) hereby notify the U.S. Patent and Trademark Office of the document(s) which is/are listed on the attached Form PTO-SB/08A. Copies of references are enclosed.

X (1) This IDS does NOT require a fee or 37 C.F.R. § 1.97(e) statement because it is
being filed (check all that apply):
X (a) Within three months of the filing date of a national application other than a

continued prosecution application under § 1.33(a), OK
(b) Within three months of the date of entry of the national stage as set forth in §
1.491 in an international application; <b>OR</b>

	(c) Befo	re the r	nailing c	of a	first	Office	action	on the	merits;	OR
--	----------	----------	-----------	------	-------	--------	--------	--------	---------	----

continued prosecution application under & 1.53(d): OR

Attorney Docket No. 2414109
(d) Before the mailing of a first Office action after the filing of a request for
continued examination under § 1.114.
(2) This information disclosure statement is filed before the mailing date of a final
action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes
prosecution in the application, and (check only one):
(a) Is accompanied by the fee set forth in § 1.17(p); OR
(b) Each item of information contained in the information disclosure statement was
first cited in any communication from a foreign patent office in a counterpart foreign application
not more than three months prior to the filing of the information disclosure statement; OR
(c) No item of information contained in the information disclosure statement was
cited in a communication from a foreign patent office in a counterpart foreign application, and to
the knowledge of the person signing the certification after making reasonable inquiry, no item of
information contained in the information disclosure statement was known to any individual
designated in § 1.56(c) more than three months prior to the filing of the information disclosure
statement.
(3) This Information disclosure statement is filed on or before payment of the issue
fee and is accompanied by the fee set forth in § 1.17(p); AND (check only one):
(a) Each item of information contained in the information disclosure statement was
first cited in any communication from a foreign patent office in a counterpart foreign application
not more than three months prior to the filing of the information disclosure statement; OR
(b) No item of information contained in the information disclosure statement was
cited in a communication from a foreign patent office in a counterpart foreign application, and to

the knowledge of the person signing the certification after making reasonable inquiry, no item of

10/516864

Attorney Docket No. 241410

DT05 Rec'd PCT/PT0 0 3 DEC 2004

information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant(s) does/do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Please charge any necessary fee or credit any overpayment in connection with this Information

Disclosure Statement to Deposit Account No. 13-0480 (please reference 32144183.4).

Respectfully submitted

Pamela J. Wong

Attorney for Applicant

Reg. No. 54,765

12/3/2004

BAKER & MCKENZIE 2300 Trammell Crow Center

2001 Ross Avenue

Dallas, Texas 75201-2916

Main: (214) 978-3000 Direct: (619) 235-7792

Fax: (214) 978-3099



## DT05 Rec'd PCT/PTO 0 3 DEC 2004

PTO/SB/08A (08-03) Approved for use unough 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known			
Application Number Initial filing			
Filing Date			
First Named Inventor	Hsiao		
Art Unit	Not yet assigned		
	Application Number Filing Date First Named Inventor		

(Use as many sheets as necessary) **Examiner Name** Not yet assigned Attorney Docket Number 32144183.4 Sheet

Examiner	U. S. PATENT DOCUMENTS  xaminer   Cite   Document Number   Publication Date   Name of Patentee or   Pages, Columns, Lines, Where									
Initials*	Cite No. <sup>1</sup>	Number-Kind Code <sup>2 (¶ known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear					
		<sup>US-</sup> 2002/0106685A1	08/08/2002	Henning et al.						
		US-								
		US-								
		US-								
		US-								
		US-								
		US-								
		US-								
		US-								
		US-								
		US-								
		US-								
		US-			*					
		US-								
		US-								
		US-								
		US-								
		US-								
		US-								


	•	FORE	GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>
	<u> </u>					
						<u></u>
	ļ					
				l	1	

	_	
Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.





## DT05 Rec'd PCT/PTO 0 3 DEC 2004

PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known			
				Application Number	Initial Filing	
INF	ORMATION	DIS	CLOSURE	Filing Date		
STA	STATEMENT BY APPLICANT			First Named Inventor	HSIAO et a.	
ĺ	Also as many sho	n se stor	ecessary)	Art Unit	Not yet assigned	
(Use as many sheets as necessary)			ecessary,	Examiner Name	Not yet assigned	
Sheet	2	of	2	Attorney Docket Number	32144183.4	

Examiner	Cite	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	T
nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MULCAHY et al. Cancer and mutant DNA in blood plasma. The Lancet. 07 September 1996, Vol. 348, pp. 28.	
		ANKER et al. Detection of circulating tumour DNA in the blood(plasma/serum) of cancer patients. Cancer and Metastasis Reviews. 1999, Vol. 18, pps. 65-73.	
		VALIZADEH et al. Expression of E-cadherin-associate molecules (alpha, beta and gamma-catenins a p 120) in colorectal polyps. Am. J. Pathology. June 1997, Vol. 150, No. 6, pps. 1977-1984	
		QIN et al. The prognostic molecular markers in hepatocellular carcinoma. World AJ. Gastroenterol. 2002, Vol. 8, No. 3, pps. 385-392.	

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.